D-Dimer Testing Market Size Is Expected To Reach USD 1.7 Billion By 2027

 D-dimer Testing Industry Overview

The global D-dimer testing market size was valued at USD 1.2 billion in 2019 and is expected to grow at a compound annual growth rate (CAGR) of 4.3% from 2020 to 2027. A paradigm shift towards the demand for next-generation point-of-care D-dimer testing has driven the market. This is because the implementation of POC solutions significantly reduces waiting time, minimizes the length of patient stay, enables faster diagnosis, and results in improved patient experience. The resounding benefits gained from these solutions in POC settings are considered to boost the growth of the market for D-dimer testing. A rise in the incidence rate of Venous Thromboembolism (VTE) coupled with various pulmonary and cardiovascular diseases that cause life-threatening issues due to blood clot formation is increasing the demand for D-dimer testing.

As per estimates of the Centers for Disease Control and Prevention (CDC), around 900,000 people are affected with VTE each year and nearly 60,000-100,000 Americans die due to VTE in the U.S. The advent of aptamers that can reduce the use of antibodies for D-dimer testing is proven to be a cost-effective and long-lasting approach in D-dimer testing. Aptamers are also affordable, stable, and faster to produce as well as possess a longer shelf life as compared to antibodies, thus creating lucrative opportunities for market growth. For instance, aptamers provided by Ayass Bioscience, LLC are observed to be useful in homogeneous assays and manual POC agglutination tests.

Gather more insights about the market drivers, restrains and growth of the Global D-dimer Testing market

Extensive research studies have predicted that elevated D-dimer levels serve as a valuable marker in several clinical conditions, such as atrial fibrillation, HIV infection, coronary artery disease, and acute pancreatitis. For instance, systemic alterations in coagulation are related to complications of acute pancreatitis. Hence, D-dimer levels can be used in the risk assessment of acute pancreatitis. Such research findings are anticipated to broaden the application scope of these tests.

The effects of heterophilic antibodies on the estimation of the D-dimer level remain a big challenge in the clinical examination of cardiac and other diseases. This results in significant differences in the end results. Studies suggest that the combination of instrumental methods, incorporation of heterophilic antibody blockers along with clinical performance and imaging data can rule out this interference, thus pronouncing the need for further research in this sector.

Browse through Grand View Research's Clinical Diagnostics Industry Research Reports.

• Primary Care POC Diagnostics Market - The global primary care POC diagnostics market size was estimated at USD 6.3 billion in 2016. The rapid evolution of point-of-care testing (POCT) holds enormous potential for the growth of both primary and secondary care settings. Rapidly increasing healthcare expenditure within secondary and tertiary care has driven the attention of healthcare communities toward primary care settings.

 

• Blood Screening Market - The global blood screening market size was valued at USD 1.6 billion in 2015 and is projected to grow at a CAGR of 10.2% over the forecast period. Blood screening is a process in which donated blood is screened for various infectious diseases such as HBV, HCV, HIV1, and HIV2. High growth of this market is attributed to rising blood donations, increase in the incidence of infectious diseases, and government initiatives.

 

D-dimer Testing Market Segmentation

Grand View Research has segmented the global D-dimer testing market based on product, test type, method, application, end-use, and region:

• Product Outlook (Revenue, USD Million, 2016 - 2027)
  • Analyzers
  • Reagents & Consumables
    
    
• Test Type Outlook (Revenue, USD Million, 2016 - 2027)
  • Clinical Laboratory Tests
  • Point-of-Care Tests
    
    
• Method Outlook (Revenue, USD Million, 2016 - 2027)
  • Enzyme-linked Immunosorbent Assay (ELISA)
  • Latex-enhanced Immunoturbidimetric Assays
  • Fluorescence Immunoassays
  • Others
    
    
• Application Outlook (Revenue, USD Million, 2016 - 2027)
  • Deep Vein Thrombosis (DVT)
  • Pulmonary Embolism (PE)
  • Disseminated Intravascular Coagulation (DIC)
  • Others
    
    
• End-use Outlook (Revenue, USD Million, 2016 - 2027)
  • Hospitals
  • Academic & Research Institutes
  • Diagnostic Centers
  • Others
    
    
• Regional Outlook (Revenue, USD Million, 2016 - 2027)
• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa (MEA)

Market Share Insights

• April 2019: Ortho Clinical Diagnostics, a U.S.-based company, launched its D-Dimer assay in collaboration with Diazyme Laboratories, Inc. This new assay is one of the latest product of MicroTip Partnership Assay Program of Ortho Clinical, which allow the company to provide high value, flexible, quick, and esoteric testing solutions.
  
  

Key Companies profiled:

Some prominent players in the global D-dimer testing market include

• Thermo Fisher Scientific Inc.
• Hoffmann-La Roche Ltd.
• Siemen Healthineers
• Abbott
• biomérieux SA
• WERFEN
• HORIBA, Ltd.
• Quidel Corporation
• Diazyme Laboratories, Inc.
• Biomedica Diagnostics
• Sekisui Diagnostics
  
  

Order a free sample PDF of the D-dimer Testing Market Intelligence Study, published by Grand View Research.